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Purpose: Inadequate empirical therapy for severe infections caused by extended-
spectrum β-lactamase-producing Escherichia coli (ESBLEC) is associated with poor 
outcomes. This study was designed to investigate risk factors for community-onset 
ESBLEC bacteremia at admission to a tertiary care hospital. Materials and Meth-
ods: A case-control study was performed that included all episodes of ESBLEC bac-
teremia in the outpatient department or within 48 hours of admission from January 
2005 to March 2009. Data on predisposing factors were collected. The molecular epi-
demiology of ESBLEC clinical isolates was also determined. Results: Among 25281 
blood cultures, 60 episodes of ESBLEC bacteremia were studied, which accounted 
for 7% of all E. coli bacteremia at admission. Healthcare-associated infection [odds 
ratio (OR), 8.3; 95% confidence interval (CI), 2.4-28.7; p=0.001], malignancy (OR, 
4.6; 95% CI, 1.3-16.3; p=0.018), urinary tract infection (OR, 139.1; 95% CI, 24.6-
788.2; p<0.001), hepatobiliary infection (OR, 79.1; 95% CI, 13.5-463.8; p<0.001), 
third generation cephalosporin usage during preceding 3 months (OR, 16.4; 95% CI, 
2.0-131.8; p=0.008), and severe sepsis/septic shock (OR, 73.7; 95% CI, 12.4-438.5; 
p<0.001) were determined as independent risk factors for community-onset ES-
BLEC bacteremia. The most common extended-spectrum β-lactamase (ESBL) gene 
identified was blaCTX-M-15 (n=31) followed by blaCTX-M-14 (n=23). Conclusion: The 
most common types of ESBLs in E. coli causing community-onset bacteremia were 
CTX-M-15 and CTX-M-14 in Korea. By result of decision tree analysis, the empiri-
cal use of carbapenems is suggested only for patients with severe sepsis/septic shock, 
hepatobiliary infection, or healthcare-associated urinary tract infection.
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INTRODUCTION
Extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) is an emerg-
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were ≤18 years old or did not have a blood culture within 48 
hrs of admission were excluded from the control group.
Variables analyzed as possible risk factors included age, 
sex, associated diseases, severity of comorbidity according 
to the Charlson score,8 healthcare-associated infection, 
source of bacteremia, invasive procedure such as urinary 
catheter or tracheostomy during the preceding three months, 
antimicrobial therapy during preceding three months, pres-
ence of severe sepsis or septic shock, and severity of illness 
as calculated by the Pitt bacteremia score.9 
The presence of the following associated diseases was 
documented: diabetes mellitus, heart failure, chronic pulmo-
nary disease, chronic renal insufficiency, liver cirrhosis, and 
malignancy. Healthcare-associated infections were classified 
in accordance with the definition by Friedman, et al.10 with 
some modifications. Any of the following criteria were con-
sidered as healthcare-associated infections: intravenous ther-
apy, wound care, or nursing care received at home 30 days 
before the bloodstream infection; attendance at a hospital or 
hemodialysis clinic or receipt of intravenous chemotherapy 
30 days before the bloodstream infection; >48-hour hospital 
admission or performance of invasive procedures such as 
urinary catheter, endoscopy, and naso-gastric tube 90 days 
before the bloodstream infection; or residence at a nursing 
home or long-term care facility. Source of the infection was 
determined to be the urinary tract, hepatobiliary, gastroin-
testinal, respiratory, other soft-tissue infection, or primary 
bloodstream infection.
The study was approved by the Institutional Review 
Boards of the hospital (GIRBA 2212). 
Microbiologic studies
Isolates were identified using a Vitek GNI card (bioMéri-
eux, Marcy l’Etoile, France). Antimicrobial susceptibilities 
were tested by disk diffusion test on Mueller-Hinton agar 
(Difco, Cockeysville, MI, USA) and by the agar dilution 
method according to the interpretative criteria proposed by 
the Clinical and Laboratory Standards Institute.11 The pheno-
typic confirmatory test for ESBL and/or AmpC β-lactamase 
was performed.12 Detection of genes coding for plasmid-
borne ESBLs and AmpC β-lactamases was performed by 
PCR amplification with primers as described previously.7 
The templates for PCR amplification in clinical isolates 
were whole cell lysates, and the PCR products were sub-
jected to direct sequencing. The agar mating method was 
used to test transferability of oxyimino-cephalosporin resis-
tance determinants using azide-resistant E. coli J53 as a re-
ing cause of nosocomial, healthcare-associated, and commu-
nity-acquired infections worldwide.1 Inadequate empirical 
antibiotic therapy for infections caused by this microorgan-
ism is associated with poor outcomes,2-4 especially in severe 
infections.5 Considering the increased prevalence of ES-
BLEC, elucidation of risk factors for ESBLEC bacteremia is 
critical in terms of empirical treatment of the patients. Al-
though there have been several studies for infections caused 
by extended-spectrum β-lactamase (ESBL)-producing En-
terobacteriaceae, only a few studies have investigated the 
risk factors for ESBLEC bacteremia. 
The CTX-M enzymes are spreading rapidly and are now 
the dominant type of ESBL in E. coli in many parts of the 
world.6 Among CTX-M enzymes, members of the CTX-
M-1 and CTX-M-9 clusters have repeatedly been found 
worldwide including Korea.7
This study was designed to investigate risk factors for 
community-onset ESBLEC bacteremia at the time of ad-
mission to a tertiary care hospital. Decision-tree analysis 
using the classification and regression tree (CART) algo-
rithm was performed to predict which subgroup of patients 
who had a blood culture within 48 hours of admission was 
at increased risk of being infected by ESBLEC bacteremia. 
The molecular epidemiology of ESBLEC isolates obtained 
from patients with bacteremia was also determined.
MATERIALS AND METHODS
　　　
Background, setting, and design
This study was conducted at the Gachon University Gil 
Medical Center, a 1200 bed tertiary care facility located in 
Incheon, Republic of Korea. The ESBLEC strains were 
isolated from the blood cultures of patients from January 
2005 through March 2009. 
The risk factors for community-onset ESBLEC bactere-
mia were investigated using a case-control design. A case 
was defined as an adult (>18 years) with ESBLEC bactere-
mia that was present in the outpatient department or within 
48 hrs of admission to the hospital. Patients with positive 
blood cultures for ESBLEC, which recovered after 48 hours 
of admission, were excluded from the study. The first blood 
isolate per case was studied. Controls were chosen among 
the patients who had a blood culture performed in the outpa-
tient department or within 48 hrs of admission in the study 
period if their blood culture did not yield ESBLEC. For each 
case, three controls were randomly selected. Patients who 
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excluded from the analysis because they were positive for 
TEM-1 without SHV-, CTX-M-type ESBL genes. 
 
Risk factors for ESBLEC bacteremia at admission
Univariate analysis showed that age >60 years old; liver 
cirrhosis; malignancy; Charlson comorbidity index; health-
care-associated infection; urinary tract, hepatobiliary, or re-
spiratory tract as the infection source; indwelling urinary 
catheter; naso-gastric tube; third generation cephalosporin 
and quinolone usage during preceding three months of ad-
mission; septic shock/severe sepsis; and severity of illness 
as calculated by the Pitt bacteremia score were associated 
with ESBLEC bacteremia at admission (Table 1). Results 
of the multivariate logistic regression analysis are presented 
in Table 2. In the final model, healthcare-associated infec-
tion (OR, 8.3; 95% CI, 2.4-28.7; p=0.001), malignancy 
(OR, 4.6; 95% CI, 1.3-16.3; p=0.018), urinary tract infection 
(OR, 139.1; 95% CI, 24.6-788.2; p<0.001), hepatobiliary in-
fection (OR, 79.1; 95% CI, 13.5-463.8; p<0.001), third gen-
eration cephalosporin usage during preceding 3 months 
(OR, 16.4; 95% CI, 2.0-131.8; p=0.008) and severe sepsis/
septic shock (OR, 73.7; 95% CI, 12.4-438.5; p<0.001) were 
identified as independent risk factors for ESBLEC bactere-
mia at admission. The fitness of the final multiple logistic 
regression model was excellent (area under ROC curve, 
0.96; 95% CI, 0.94-0.99). The CART analysis included the 
six variables significant in the multivariate logistic regres-
sion analysis, and identified severe sepsis/septic shock at 
presentation as the best single discriminator between ESBL 
bacteremia and no ESBL bacteremia. The next best predic-
tor of ESBL bacteremia in no severe sepsis/septic shock 
node was urinary tract infection. For the node with patients 
without severe sepsis/septic shock and no urinary tract in-
fection, hepatobiliary infection provided additional predic-
tive value. For the node with patients without severe sepsis/
septic shock, urinary tract infection, or hepatobilary infec-
tion, healthcare-associated infection provided additional 
predictive value (Fig. 1).  
 
Microbiologic results
All 60 isolates showed positive results in the phenotypic con-
firmatory test, indicating ESBL production. The most com-
mon type of ESBL gene identified was blaCTX-M-15 (n=31) fol-
lowed by blaCTX-M-14 (n=23). Other types of ESBL gene, such 
as blaCTX-M-22 (n=2), blaCTX-M-24 (n=1), blaCTX-M-57 (n=1), and 
blaSHV-12 (n=2) were also identified. Annual percentages of 
ESBL-producing isolates in community-onset bacteremic E. 
cipient. Transconjugants were selected on Mueller-Hinton 
agar plates supplemented with 2 µg/mL cefotaxime and 
100 µg/mL sodium azide.13
Pulsed-field gel electrophoresis (PFGE) was performed 
with XbaI restriction enzyme using a CHEF-DRII device 
(Bio-Rad, Hercules, CA, USA). Tiff format gel images were 
exported to Molecular Analyst Fingerprinting Software Ver. 
3.2 (Bio-Rad) for analysis. Comparisons for E. coli isolates 
were made by using the band-based dice coefficient. Den-
drograms were generated using the unweighted pair group 
method with arithmetic averages method with 1.0% position 
tolerance. Multilocus sequence typing (MLST) was per-
formed on ESBLEC isolates using seven conserved house-
keeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA) 
following protocols at http://mlst.ucc.ie/mlst/dbs/Ecoli. 
 
Statistical analysis
Univariate analyses were performed separately for each of 
the variables. Odds ratios (ORs) and 95% confidence inter-
vals (CIs) were calculated for binomial variables. p values 
were calculated using Fisher’s exact test for categorical vari-
ables. Variables with a p value of <0.1 in the univariate anal-
ysis were candidates for multivariate analysis using a back-
ward elimination method. The area under the receiver 
operator characteristic (ROC) curve was calculated to eval-
uate the performance of the models. To split patients into 
more homogeneous subgroups, a CART analysis was used 
to build a binary classification tree through recursive parti-
tioning. All tests were 2-tailed, and a p value of <0.05 was 
considered significant in the multivariable model. STATA 
software package version 10.0 (StataCorp, College Station, 
TX, USA) was used to perform the multiple logistic regres-
sion, and R 2.4.1 (The R foundation for statistical comput-
ing) was used to construct the CART algorithm.
 
RESULTS
 
During the study period, 25281 blood cultures were taken 
from adult patients in the outpatient department or within 
48 hours of admission to the Gil Hospital. Among them, 
3452 episodes of positive blood cultures (13.7%) were for 
any organism including 891 E. coli were found, among 
which 62 were ESBL producers by phenotypic analysis. 
Since the ESBL gene could not be detected in two isolates, 
risk factors and microbiological profiles were assessed in 
60 patients with ESBLEC bacteremia. Two isolates were 
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was identified in three isolates carrying the blaCTX-M-15 gene 
and one isolate carrying the blaCTX-M-14 gene. Both isolates 
carrying the blaSHV-12 gene also carried the blaDHA-1 gene. 
Despite repeated attempts, transconjugants were obtained 
from only 21 of 60 isolates.
After all of the 60 isolates were subjected to MLST analy-
coli increased from 1% in 2005 to 21% in 2009 (p<0.001). 
Among ESBLEC isolates harboring blaCTX-M genes, the pre-
dominant CTX-M group was the CTX-M-1 group in 2005-
2007 and the CTX-M-9 group in 2008-2009 (86% and 
57%, respectively; p=0.002) (Table 3). Six ESBL-produc-
ing isolates also carried an AmpC gene. The blaCMY-2 gene 
Table 1. Univariate Analysis of Risk Factors for Community-Onset ESBL-Producing Escherichia coli Bacteremia
Risk factor Cases (n=60) Controls (n=180) OR (95% CI) p value
Age >60 yrs 44 (73) 73 (41)   4.0 (2.1-7.7) <0.001
Female sex 28 (47) 78 (43)   1.1 (0.6-2.1)   0.66
Associated disease
    Diabetes mellitus 16 (27) 32 (18)   1.7 (0.8-3.3)   0.14
    Heart failure   7 (12) 12 (7)   1.8 (0.7-4.9)   0.27
    Chronic pulmonary disease   1 (2)   9 (5)   0.3 (0.04-2.6)   0.46
    Chronic renal insufficiency   3 (5)   5 (3)   1.8 (0.4-8.0)   0.42
    Liver cirrhosis 11 (18)   4 (2)   9.9 (3.0-32.4) <0.001
    Malignancy 24 (40) 19 (11)   5.6 (2.8-11.4) <0.001
Charlson comorbidity index ≥2 40 (67) 49 (27)   5.3 (2.9-10.0) <0.001
Healthcare-associated infection 51 (85) 87 (48)   6.1 (2.8-13.0) <0.001
Source of infection
    Primary   6 (10) 22 (12)   0.8 (0.3-2.1)   0.82
    Urinary 33 (55) 22 (12)   8.8 (4.5-17.3) <0.001
    Hepatobiliary 26 (43) 15 (8.3)   8.4 (4.0-17.5) <0.001
    Gastrointestinal   5 (8) 26 (14)   0.5 (0.2-1.5)   0.27
    Respiratory   5 (8) 48 (27)   0.3 (0.09-0.7)   0.002
    Skin and soft tissue   1 (2) 14 (8)   0.2 (0.03-1.6)   0.12
Device
    Urinary catheter 15 (25) 10 (6)   5.7 (2.4-13.5) <0.001
    Tracheostomy/intubation   3 (5)   3 (2)   3.1 (0.6-15.8)   0.17
    Naso-gastric tube   6 (10)   5 (3)   3.9 (1.1-13.2)   0.03
Previous antimicrobial  usage
    Cephalosporins
        First generation   4 (7)   4 (2)   3.1 (0.8-13.0)   0.11
        Second generation   2 (3)   3 (2)   2.0 (0.3-12.5)   0.60
        Third generation 17 (28)   7 (4)   9.8 (3.8-25.0) <0.001
    Penicillins   2 (3)   1 (1)   6.2 (0.6-69.3)   0.15
    Quinolones 10 (17)   5 (3)   7.0 (2.3-21.4)   0.001
    Septic shock/severe sepsis 26 (43) 10 (6) 13.0 (5.7-29.4) <0.001
    Pitt bacteremia score ≥2 24 (40) 25 (14)   4.1 (2.1-8.1) <0.001
ESBL, extended-spectrum β-lactamase; OR, odds ratio; CI, confidence interval.
Data are presented as no. (%) of patients.
Table 2. Multivariate Analysis of Risk Factors for Community-Onset ESBL-Producing Escherichia coli Bacteremia
Risk factor Adjusted OR (95% CI) p value
Healthcare-associated infection     8.3 (2.4-28.7) 0.001
Malignancy     4.6 (1.3-16.3) 0.018
Urinary tract infection 139.1 (24.6-788.2) <0.001
Hepatobiliary infection   79.1 (13.5-463.8) <0.001
Previous third generation cephalosporin usage   16.4 (2.0-131.8) 0.008
Severe sepsis/septic shock   73.7 (12.4-438.5) <0.001
ESBL, extended-spectrum β-lactamase; OR, odds ratio; CI, confidence interval.
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molecular epidemiology of community-onset ESBLEC 
bloodstream infection. Because ESBL-producing bacteria 
are often resistant to various antimicrobials including fluo-
roquinolones and oxyimino-cephalosporins, the presence of 
these enzymes complicates the selection of empirical anti-
biotics while the results of cultures and antimicrobial suscep-
tibility profiles are awaited. Several studies have addressed 
the impact of inadequate empirical antimicrobial treatment 
in patients with infections caused by ESBL producers.3,14 A 
delay or failure in initiating adequate antimicrobial therapy 
was associated with increased morbidity and mortality in se-
vere infections.5,15 Moreover, in septic patients, the impor-
tance of appropriate empirical therapy has also been empha-
sized.16-18 For effective empirical treatment, risk factor 
analysis for any bloodstream infection by ESBL producers 
has important clinical implications. Although there have been 
numerous reports of infections or colonization with ESBL-
producing organisms in recent years, only five studies have 
been conducted to analyze the risk factors of ESBLEC 
sis, the most commonly identified sequence type (ST) was 
ST131 (n=11) followed by ST648 (n=6), ST38 (n=4), 
ST405 (n=4), ST69 (n=3), ST95 (n=3), and ST410 (n=3). 
Other STs, including ST10, ST44, ST46, ST112, ST354, 
ST393, ST457, ST617, ST773, ST939, ST964, ST1011, 
ST1177, and ST2037, were found in one or two isolates. 
The ST2037 (85-88-78-37-59-58-62) was newly identified 
in this study. The four of 11 E. coli isolates of ST131 har-
bored the blaCTX-M-15 gene. The remaining seven isolates of 
ST131 carried blaCTX-M-14 (n=6) or blaSHV-12 (n=1). Banding 
patterns of XbaI-digested DNA showed less than 80% ge-
netic similarity for most of the CTX-M-type- or SHV-12-
producing isolates, which were considered to be unrelated 
(Figs. 2 and 3).
DISCUSSION
This study was designed to identify the best predictors and 
Fig. 1. Classification and regression trees analysis for predicting extended-spectrum β-lactamase (ESBL)-producing Escherichia coli bacteremia among 
adult patients who had a blood culture within 48 hours of admission to tertiary care hospital.
No severe sepsis/septic shock
No urinary tract infection
No hepatobiliary infection Community-acquired infection
Severe sepsis/septic shock
Urinary tract infection
Hepatobiliary infection Healthcare-associated infection
ESBL bacteremia=60
No ESBL bacteremia=180
Total=240
ESBL bacteremia=2
No ESBL bacteremia=134
(1.5%)
ESBL bacteremia=14
No ESBL bacteremia=149
(8.6%)
ESBL bacteremia=34
No ESBL bacteremia=170
(16.7%)
ESBL bacteremia=12
No ESBL bacteremia=15
(44.4%)
ESBL bacteremia=2
No ESBL bacteremia=13
(13.3%)
ESBL bacteremia=20
No ESBL bacteremia=21
(48.8%)
ESBL bacteremia=26
No ESBL bacteremia=10
(72.2%)
ESBL bacteremia=18
No ESBL bacteremia=8
(69.2%)
Table 3. Percentage of ESBL Production and Distribution of CTX-M Enzyme in Community-Onset Escherichia coli Bacteremia
Yr
No. of isolates
Blood 
culture
E. coli
ESBL producer 
(% of E. coli)
CTX-M
CTX-M-1 group CTX-M-9 group
SHV-12
M-15 M-22 M-57 M-14 M-24
2005   5598 191   2 (1)   2   2
2006   5280 201 12 (6) 10   8 1   1 2
2007   5897 187   9 (5)   9   6 1   2
2008   6768 245 23 (9) 23   9 14
2009*   1738   67 14 (21) 14   6 1   6 1
Total 25281 891 60 (7) 58 31 2 1 23 1 2
ESBL, extended-spectrum β-lactamase.
*From January to March, 2009.
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organism were used as control patients, these ‘susceptible 
control patients’ (i.e., patients with non-ESBL producing E. 
coli bacteremia) would not be representative of the ‘source 
population’ for antimicrobial resistant organisms, and this 
may lead to an overestimation of the association between 
antimicrobial exposure and cases.24-26 
The CART analysis is a statistical method based on a re-
cursive partitioning analysis. Unlike multivariate logistic re-
gression, by which the odds ratio produced can be difficult 
to translate, CART is well suited clinical decisions on rules 
and produces decision trees that are simple to interpret. 
CART has been successfully used to assist in the diagnosis 
of various clinical conditions including infections27,28 and 
neurological,29 oncological,29,30 and cardiac disorders.31 Ac-
cording to our results, the empirical use of carbapenems is 
suggested for patients with severe sepsis/septic shock, hep-
bloodstream infections.19-23 Although two studies have in-
vestigated the risk factors for community-onset blood-
stream infections of ESBLEC,21,22 as risk factors may differ 
according to geographic variation and patient population, 
empirical antibiotic choices should be individualized. 
In the present study, we selected control patients from all 
adult patients who had a blood culture in the outpatient de-
partment or within 48 hours of admission to Gil Hospital to 
investigate the risk factors of ESBLEC bacteremia among 
patients who were septic; therefore blood cultures were tak-
en at presentation. Although some of the documented risk 
factors in this study might be those of a susceptible organ-
ism (non-ESBL producing E. coli),24 we believe that our re-
sults certainly give clinical clues as to what subpopulation 
of the patients need empirical therapy for ESBLEC bactere-
mia. If patients infected with the antimicrobial susceptible 
Isolate ESBL gene Conjugability ST adk fumC gyrB icd mdh purA recA
E06358 blaCTX-M-15 No 10 10 11 4 8 8 8 2
E07483 blaCTX-M-15 No 617 10 11 4 8 8 13 74
E09060 blaCTX-M-15 No 648 92 4 87 96 70 58 2
E07354 blaCTX-M-15 No 648 92 4 87 96 70 58 2
E08414 blaCTX-M-15 Yes 95 37 38 19 37 17 11 26
E08342 blaCTX-M-15 Yes 46 8 7 1 8 8 8 6
E09156 blaCTX-M-15 No 405 35 37 29 25 4 5 73
E09071 blaCTX-M-15 No 131 53 40 47 13 36 28 29
E09115 blaCTX-M-15 No 648 92 4 87 96 70 58 2
E060236 blaCTX-M-15 No 131 53 40 47 13 36 28 29
E061321 blaCTX-M-15 No 95 37 38 19 37 17 11 26
E06269 blaCTX-M-15 Yes 648 92 4 87 96 70 58 2
B070151 blaCTX-M-22 Yes 69 21 35 27 6 5 5 4
E08581 blaCTX-M-15 No 939 80 4 33 16 7 8 6
E06070 blaCTX-M-22 Yes 410 6 4 12 1 20 18 7
E07348 blaCTX-M-15 No 131 53 40 47 13 36 28 29
E06027 blaCTX-M-15 No 648 92 4 87 96 70 58 2
E08626 blaCTX-M-15, blaCMY-2 No 1177 4 26 2 211 5 5 19
E05086 blaCTX-M-15 Yes 410 6 4 12 1 20 18 7
B061647 blaCTX-M-15 Yes 1011 6 4 159 44 112 1 17
E09061 blaCTX-M-57 Yes 69 21 35 27 6 5 5 4
E08013 blaCTX-M-15 No 44 10 11 4 8 8 8 7
E09030 blaCTX-M-15, blaCMY-2 No 410 6 4 12 1 20 18 7
E09037 blaCTX-M-15 Yes 410 6 4 12 1 20 18 7
B061803 blaCTX-M-15 No 648 92 4 87 96 70 58 2
E08396 blaCTX-M-15, blaCMY-2 Yes 410 6 4 12 1 20 18 7
E05051 blaCTX-M-15 No 410 6 4 12 1 20 18 7
E07042 blaCTX-M-15 No 648 92 4 87 96 70 58 2
E07294 blaCTX-M-15 No 131 53 40 47 13 36 28 29
B081459 blaCTX-M-15 No 44 10 11 4 8 8 8 7
E06476 blaCTX-M-15 No 410 6 4 12 1 20 18 7
E06180 blaCTX-M-15 No 410 6 4 12 1 20 18 7
E08284 blaCTX-M-15 Yes 112 13 44 9 22 16 30 34
E08437 blaCTX-M-15 No 964 35 183 29 25 4 5 73
Fig. 2. Dendrogram based on XbaI-macrorestriction patterns of E. coli isolates producing CTX-M-1-type ESBLs. The dashed line indicates 80% similarity. E. 
coli isolates exhibiting similarities of <80% were considered unrelated. *XbaI-macrorestriction analysis yielded no DNA banding patterns due to the degen-
eration of the genomic DNA during preparation of the agarose plugs. ESBL, extended-spectrum β-lactamase.
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currently, the most prevalent CTX-M enzyme worldwide is 
CTX-M-15, which has been reported in Europe, Asia, Africa, 
North America, South America, and Australia.36 The pre-
dominance of CTX-M-15 and CTX-M-14 is in agreement 
with recent reports in Korea.37-39 Moreover, the presence of 
the CTX-M-9 group is increasing in Korea. In the present 
study, the most predominant CTX-M group was the CTX-
M-1 group in 2005-2007 and the CTX-M-9 group in 2008-
2009 among all ESBLEC isolates having blaCTX-M genes 
(86% and 57%, respectively, p=0.002). The rate of ESBL 
production among E. coli from the blood of patients with 
community-onset bacteremia was 7% and increased 21 
times from 2005 to 2009. This change may be attributable 
to the dissemination of CTX-M enzymes since the blaCTX-M 
genes were detected in 58 (97%) of 60 ESBLEC isolates. 
Further studies are required to obtain more information on 
the prevalence of ESBL producers and changes to the mo-
lecular epidemiology of CTX-M enzymes in the Republic 
of Korea. 
The E. coli O25:H4-ST131 has been recognized as an 
emerging intercontinental clonal group expressing CTX-M-
type ESBL. Most previous studies from Europe and North 
atobiliary infection, or healthcare-associated urinary tract 
infection. Before the present risk factors might be applied 
to clinical decisions for empirical therapy, the limitations 
for our study must be considered. This study was performed 
with a relatively small number of patients in a single center. 
In addition, documented risk factors in our study were based 
on data that is several years old. Clinicians should take into 
account that the epidemiology of Enterobacteriaceae chang-
es rapidly, which was underlined by the major change in ES-
BLEC prevalence in this study population. Moreover, in-
creasing carbapenem resistance, mediated by porin loss or 
carbapenemases, should be considered32 because the pres-
ence of carbapenem-resistant Enterobacteriaceae has been 
reported worldwide including the Republic of Korea.33 
The predominance of CTX-M enzymes and clonally un-
related isolates are consistent with the fact that ESBLEC is 
a true community pathogen. Although healthcare-associat-
ed infection was associated with an increased risk of ES-
BLEC bacteremia in our study, it could be a surrogate mark-
er because ESBLEC colonization is mainly a problem in 
the community.1,34,35 Although CTX-M-9 group enzymes 
are the most prevalent ESBLs in Spain, China, and Taiwan, 
Isolate ESBL gene Conjugability ST adk fumC gyrB icd mdh purA recA
E08230 blaCTX-M-14 No 131 53 40 47 13 36 28 29
B090280 blaCTX-M-14 Yes 95 37 38 19 37 17 11 26
B080048 blaCTX-M-14 No 648 92 4 87 96 70 58 2
E08436 blaCTX-M-14 No 405 35 37 29 25 4 5 73
E08558 blaCTX-M-14 No 405 35 37 29 25 4 5 73
E06368 blaSHV-12, blaDHA-1 Yes 131 53 40 47 13 36 28 29
E08344 blaCTX-M-14 No 131 53 40 47 13 36 28 29
E09069 blaCTX-M-14 No 131 53 40 47 13 36 28 29
E08248 blaCTX-M-14 Yes 773 6 165 4 17 7 8 6
E08374 blaCTX-M-14 Yes 69 21 35 27 6 5 5 4
E08420 blaCTX-M-14 No 131 53 40 47 13 36 28 29
E09038 blaCTX-M-14 No 38 4 26 2 25 5 5 19
E07495 blaCTX-M-14 No 405 35 37 29 25 4 5 73
E08132 blaCTX-M-14 Yes 393 18 106 17 6 5 5 4
E08032 blaCTX-M-14 Yes 131 53 40 47 13 36 28 29
E08331 blaCTX-M-14 Yes 457 101 88 97 108 26 79 2
E09116 blaCTX-M-14 No 38 4 26 2 25 5 5 19
B090371 blaCTX-M-14 Yes 10 10 11 4 8 8 8 2
B081373 blaCTX-M-14 No 38 4 26 2 25 5 5 19
E09180 blaCTX-M-14, blaCMY-2 Yes 131 53 40 47 13 36 28 29
E07409 blaCTX-M-14 No 354 85 88 78 29 59 58 62
E08398 blaCTX-M-14 Yes 2037 58 88 78 37 59 58 62
E06380 blaSHV-12, blaDHA-1 Yes 95 37 38 19 37 17 11 26
B061079 blaCTX-M-14 Yes 405 35 37 29 25 4 5 73
E08283 blaCTX-M-14 Yes 393 18 106 17 6 5 5 4
E09047 blaCTX-M-24 No 38 4 26 2 25 5 5 19
Fig. 3. Dendrogram based on XbaI-macrorestriction patterns of E. coli isolates producing CTX-M-9-type and SHV ESBLs. The dashed line indicates 80% sim-
ilarity. E. coli isolates exhibiting similarities of <80% were considered unrelated. *XbaI-macrorestriction analysis yielded no DNA banding patterns due to the 
degeneration of the genomic DNA during preparation of the agarose plugs. ESBL, extended-spectrum β-lactamase
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3. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Pos-
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bloodstream infections caused by extended-spectrum-beta-lac-
tamase-producing Enterobacteriaceae: importance of inadequate 
initial antimicrobial treatment. Antimicrob Agents Chemother 
2007;51:1987-94. 
4. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de 
Cueto M, Ríos MJ, et al. Bacteremia due to extended-spectrum 
beta -lactamase-producing Escherichia coli in the CTX-M era: a 
new clinical challenge. Clin Infect Dis 2006;43:1407-14.
5. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, 
Lautenbach E. Impact of inadequate initial antimicrobial therapy 
on mortality in infections due to extended-spectrum beta-lac-
tamase-producing enterobacteriaceae: variability by site of infec-
tion. Arch Intern Med 2005;165:1375-80.
6. Rossolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-
M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 
2008;14 Suppl 1:33-41.
7. Ryoo NH, Kim EC, Hong SG, Park YJ, Lee K, Bae IK, et al. Dis-
semination of SHV-12 and CTX-M-type extended-spectrum beta-
lactamases among clinical isolates of Escherichia coli and Klebsi-
ella pneumoniae and emergence of GES-3 in Korea. J Antimicrob 
Chemother 2005;56:698-702. 
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method 
of classifying prognostic comorbidity in longitudinal studies: de-
velopment and validation. J Chronic Dis 1987;40:373-83.
9. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas 
JM, Goossens H, et al. International prospective study of Klebsiel-
la pneumoniae bacteremia: implications of extended-spectrum be-
ta-lactamase production in nosocomial Infections. Ann Intern Med 
2004;140:26-32.
10. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, 
Briggs JP, et al. Health care--associated bloodstream infections in 
adults: a reason to change the accepted definition of community-
acquired infections. Ann Intern Med 2002;137:791-7.
11. Cockerill FR. Performance Standards for Antimicrobial Suscepti-
bility Testing; Twentieth Informational Supplement. Wayne, PA: 
CLSI; 2010.
12. Song W, Jeong SH, Kim JS, Kim HS, Shin DH, Roh KH, et al. 
Use of boronic acid disk methods to detect the combined expres-
sion of plasmid-mediated AmpC beta-lactamases and extended-
spectrum beta-lactamases in clinical isolates of Klebsiella spp., 
Salmonella spp., and Proteus mirabilis. Diagn Microbiol Infect 
Dis 2007;57:315-8. 
13. Jacoby GA, Han P. Detection of extended-spectrum beta-lac-
tamases in clinical isolates of Klebsiella pneumoniae and Esche-
richia coli. J Clin Microbiol 1996;34:908-11.
14. Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, 
Kaye KS. Predictors of mortality in patients with bloodstream in-
fection due to ceftazidime-resistant Klebsiella pneumoniae. Anti-
microb Agents Chemother 2006;50:1715-20.
15. Peña C, Gudiol C, Calatayud L, Tubau F, Domínguez MA, Pujol 
M, et al. Infections due to Escherichia coli producing extended-
spectrum beta-lactamase among hospitalised patients: factors in-
fluencing mortality. J Hosp Infect 2008;68:116-22. 
16. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. In-
appropriate initial antimicrobial therapy and its effect on survival 
in a clinical trial of immunomodulating therapy for severe sepsis. 
Am J Med 2003;115:529-35.
17. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. 
America reported E. coli O25:H4-ST131 strains were 
CTX-M-15 producers.40-42 Our analysis of 60 community-
onset ESBLEC determined that E. coli ST131 was the most 
prevalent (18%) clonal group. The E. coli ST131 isolates car-
ried not only the blaCTX-M-15 but also blaCTX-M-14 or blaSHV-12. 
Although E. coli ST131 was the most common cause of 
community-onset ESBLEC infection, clonal expansion of 
strains carrying blaCTX-M-15 was not the main reason for the 
rapid spread in the community. This hypothesis is support-
ed by the fact that these isolates show low level of similari-
ty in PFGE analysis. Despite that many different types of 
STs among ESBLEC and the isolates showed a low-level 
similarity by PFGE, certain ESBL genes, such as blaCTX-M-14 
or blaCTX-M-15, were predominantly found among the isolates. 
This may suggest that the plasmid or conjugative transpo-
sons harboring these antibiotic resistance genes were trans-
ferred horizontally among E. coli strains. The multi-clonali-
ty of ESBLEC, shown in our study, comes not only from 
the type of ESBL genes but also from the whole genome 
including virulence and housekeeping genes, so a multi-
clonal outbreak of ESBLEC does not always correlate with 
the diversity of ESBL genes. This means that the predomi-
nance of certain type of ESBL genes may not result in the 
mono-clonal spreading of ESBLEC.
Our results showed that physicians who care for patients 
with these risk factors should consider ESBLEC as the 
causative organism of community-onset bacteremia. The 
most common types of ESBLs in E. coli causing communi-
ty-onset bacteremia were CTX-M-15 and CTX-M-14 in 
the Republic of Korea, which might have transferred hori-
zontally.
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